Some stock data isn't available right now.
Gilead Sciences Inc (GILD)
Underlying price
$151.23+0.75% today
Stock stats
- Market cap
- $186B
- Previous close
- $150.11
- Open
- $150.11
- Day's range
- $148.22 – $152.09
- 52-week range
- $108.46 – $157.29
- Volume
- 3.12M
- Avg volume
- 5.84M
- P/E ratio
- -
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
- Ticker
- GILD
- Asset class
- Equity
- Tokenized by
- 0 issuers
- Sector
- Healthcare
- Industry
- Biological Products, (no Diagnostic Substances)
- Employees
- 17,000
- Website
- gilead.com